
BTIG lowers Tvardi Therapeutics stock price target to $15 on IPF trial setback
Read More

BTIG lowers Tvardi Therapeutics stock price target to $15 on IPF trial setback
Read More
© 2023 -2024 Geneva Times| Desgined & Developed by Immanuel Kolwin